The detection of specific CHIP mutations may improve the precision of hypercholesterolaemia therapy prescription, particularly for the more costly therapies such as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. Here, PCSK9 is linked to Hypercholesterolemia.